October 26, 2018 in References Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study PJWCreative 0 Like Post 0 Comment Read More
